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Abstract
Background: The mechanisms of intradialytic increases in blood pressure are not well defined. The present study was
undertaken to assess the role of autonomic nervous system activation during intradialytic hypertensive episodes.
Methodology/Principal Findings: Continuous interbeat intervals (IBI) and systolic blood pressure (SBP) were monitored
during hemodialysis in 108 chronic patients. Intradialytic hypertensive episodes defined as a period of at least 10 mmHg
increase in SBP between the beginning and the end of a dialysis session or hypertension resistant to ultrafiltration occurring
during or immediately after the dialysis procedure, were detected in 62 out of 113 hemodialysis sessions. SBP variability, IBI
variability and baroreceptor sensitivity (BRS) in the low (LF) and high (HF) frequency ranges were assessed using the
complex demodulation technique (CDM). Intradialytic hypertensive episodes were associated with an increased (n=45) or
decreased (n=17) heart rate. The maximal blood pressure was similar in both groups. In patients with increased heart rate
the increase in blood pressure was associated with marked increases in SBP and IBI variability, with suppressed BRS indices
and enhanced sympatho-vagal balance. In contrast, in those with decreased heart rate, there were no significant changes in
the above parameters. End-of- dialysis blood pressure in all sessions associated with hypertensive episode was significantly
higher than in those without such episodes. In logistic regression analysis, predialysis BRS in the low frequency range was
found to be the main predictor of intradialytic hypertension.
Conclusion/Significance: Our data point to sympathetic overactivity with feed-forward blood pressure enhancement as an
important mechanism of intradialytic hypertension in a significant proportion of patients. The triggers of increased
sympathetic activity during hemodialysis remain to be determined. Intradialytic hypertensive episodes are associated with
higher end-of- dialysis blood pressure, suggesting that intradialytic hypertension may play a role in generation of
interdialytic hypertension.
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Introduction
During hemodialysis treatment, blood pressure usually decreas-
es with ultrafiltration and weight loss. In a significant proportion of
patients, however, the blood pressure increases during or
immediately after hemodialysis. Intradialytic hypertension has
been recognized for many years, and it is believed to occur in at
least 8–15% of patients [1]. There is no standard definition for
intradialytic hypertension; some of the most common accepted
criteria reviewed by Chazot and Jean [2] include a 15 mmHg
increase of mean arterial pressure between the start and the end of
a dialysis session [3], hypertension resistant to ultrafiltration
occurring during or immediately after the dialysis procedure [4],
or at least a 10 mmHg increase in the systolic blood pressure from
pre-to post-dialysis [5]. Recent data have shown that intradialytic
hypertension is associated with increased mortality and morbidity
[5,6].
Several mechanisms are believed to lead to intradialytic
increases in blood pressure. A positive sodium balance, resulting
in extracellular fluid overload and hypertension in dialysis patients,
is thought by many investigators to be the main cause of
intradialytic increases in blood pressure [2,7]. Other popular
hypotheses link intradialytic hypertension to variations in potas-
sium or ionized calcium concentrations [8,9], antihypertensive
drug removal during hemodialysis [10], hemoconcentration [11],
recombinant erythropoietin administration, stimulation of the
renin-angiotensin system during ultrafiltration [12], and to
hemodynamic changes including increased cardiac output and
vasoconstriction [13]. The latter is believed to be caused by
endothelial dysfunction [14] and/or with increased endothelin
secretion and altered nitric oxide/endothelin balance [13,15].
Sympathetic overactivity, believed to be generated by neuro-
hormonal mechanisms arising within the diseased kidneys, is
considered an important mechanism of hypertension in patients
with chronic renal insufficiency [16–18]. Sympathetic nervous
system activation during hemodialysis was proposed to be an
important factor in the pathogenesis of intradialytic hypertension,
via an increase in cardiac output and/or an increase in peripheral
resistance. This hypothesis was supported by initial reports on
increased plasma levels or increased turnover of cathecholamines
in uremic patients and in experimental models of renal insuffi-
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hemodialysis treatment [22,23]. Furthermore, the baseline and
intradialytic plasma levels of chatecholamines were reported to be
similar in intradialytic hypertension-prone and in sex- matched
control hemodialysis patients [15].
Sympathetic activity is best detected using microneurography
(efferent post-ganglionic muscle sympathetic nerve activity,
MSNA) and regional norepinephrine spillover technique [24].
Previous studies have shown that the basal MSNA firing was
double in hypertensive hemodialysis patients as compared with
age-matched healthy controls with normal blood pressure. Most
studies, however, were performed in patients with residual renal
function or in hemodialysis patients on a non-dialysis day
[16,17,25]. To our knowledge, no such studies were performed
in patients with intradialytic hypertension.
Since direct methods are not available or applicable in complex
patients, sympathetic activity is assessed in many studies by non-
invasive techniques. Heart rate variability (HRV), blood pressure
variability (BPV) and baroreflex function (baroreceptor sensitivity,
BRS) are the most frequently used methods to assess autonomic
nervous system function and cardiovascular variability, a measure
of the integrated control mechanisms of circulation [26]. In clinical
settings, these measurements are usually computed from contin-
uous beat to-beat recordings of heart rate and blood pressure
oscillations [26–28]. Thus, the behavior of heart rate is considered
an indirect index of adrenergic cardiovascular drive [29]. Spectral
analysis of the heart rate oscillations allows the identification of low
frequency (LF) component, believed to result from neural
mechanisms related to sympathetic and vagal outflows, and a
high frequency component (HF), related to respiration; the LF/HF
ratio is frequently used as an index of sympatho-vagal interaction
on the autonomic control of heart rate [26–28,30,31]. In humans,
alterations of the low frequency band of blood pressure variability
(LF SBP) were shown to be affected by sympathetic modulation of
vascular tone as well as by myogenic vascular function [26–
28,32].This relationship was well documented by studies measur-
ing muscle sympathetic nerve activity in healthy volunteers, in
whom sympathetic stimulation and nerve activity were associated
with predominance of LF oscillations of blood pressure and of LF
interbeat intervals [33,34]. In the recent years, in many studies,
‘‘spontaneous’’ BRS indices are also determined from continuous
beat to beat surveys of blood pressure and heart rate, without
pharmacological or external interventions. Both spontaneous and
laboratory BRS indices correlate negatively with BPV and
positively with HRV [26–28].
Complex demodulation is a newer method for assessing time
dependent changes in signals around a specific frequency. The
technique of complex demodulation (CDM) reveals instantaneous
dynamic changes in heart rate and blood pressure that are not
revealed by the standard spectral methods [35]. Therefore CDM
may be particularly suitable to assess dynamic rapid changes in the
autonomic nervous system during dialysis.
The present study was undertaken: 1. to detect increases in
blood pressure during hemodialysis, and, 2. to assess the role of
autonomic nervous system function during intradialytic hyperten-
sive episodes. This is the first report of cardiovascular variability
indices determined before and during intradialytic hypertensive
episodes using the CDM methodology.
Methods
Continuous beat to beat blood pressure recordings were
obtained during 113 routine midweek dialysis sessions in 108
chronic patients on maintenance hemodialysis. Patients with
chronic atrial fibrillation or frequent ventricular premature beats,
with debilitating illness and frequent hospital admissions, with
permanent pacemakers or with severely decreased radial pulses
following multiple vascular access surgical interventions were
excluded from the study. Antihypertensive drugs were stopped 12–
14 hr before the dialysis session. The study was approved by
Hadassah Medical Organization Ethics Committee for Clinical
Research. The patients signed an informed consent form before
taking part in the study.
Demographic, clinical and laboratory data of all patients are
shown in Tables 1 and 2. The patients were dialyzed 3.5 to
4 hours three to four times weekly, using the Gambro AK 200
delivery system and polyamide high flux dialyzers. The mean urea
reduction rate (%URR) in all patients was 65–75%. Data on
dialysate sodium concentration are given in Table 2; dialysate
chloride, bicarbonate, potassium, dextrose and calcium concen-
trations were 108, 35, 2, 12 and 1.5 mmol/l, respectively.
The ultrafiltration rate during dialysis sessions never exceeded
1 liter/hour and was adjusted according to the presumed dry
weight. The temperature of the dialysate was kept constant at
36uC.
All patients were treated with recombinant erythropoietin and
phosphate binders (calcium carbonate, lanthanum carbonate and
sevelamer hydrochloride) as needed.
Blood pressure signal acquisition
Blood pressure and inter-beat intervals were measured nonin-
vasively by Finometer 1.10 (FMS, Finapres Medical Systems BV,
Arnhem, The Netherlands). Continuous beat to beat recording of
the finger arterial pressure waveform was performed as previously
described [36] using the volume-clamp method of Penaz [37] and
the Physiocal criteria of Wesseling [38]. In the volume-clamp
method the diameter of the finger artery under the inflated cuff is
kept constant. Changes in the arterial diameter, detected by a
photo-plethysmographic method cause, via fast servo controller,
pressure changes in an inflatable air bladder within the finger cuff.
The Physiocal algorithm adjusts the correct diameter at which the
finger artery is clamped. The transmural pressure is therefore zero
all the time i.e., the finger cuff pressure equals the intra-arterial
pressure. The finger cuff was wrapped on the middle phalanx of
the middle finger. A height correction unit was attached to correct
for finger height changes during the recording. An upper arm cuff
unit was also attached and used to calibrate the systolic pressure
for calculating the reconstructed brachial pressure from the finger
pressure.
The data from Finometer were downloaded into a PC and
analyzed by the BeatScope Software (TNO TPD Biomedical
Instrumentation Amsterdam, The Netherlands) and our specifi-
cally designed programs. The BeatScope software performs beat to
beat analysis of the finger arterial pressure and uses filtering and
level correction to calculate reconstructed brachial pressures from
finger pressures. The resulted data files containing beat to beat
values of hemodynamic variables such as inter-beat intervals (IBI),
systolic (SBP), diastolic (DBP) and mean blood pressures (MBP),
were used for further processing. Data files included beat to beat
values for the whole duration of hemodialysis. SBP and IBI signals
were resampled at 1 Hz to obtain equidistant time series [35].
Aliasing was negligible as the Nyquist frequency is 0.5 Hz for this
sampling rate and it was found to be above the frequency content
of SBP and IBI signals. The recordings were scanned for
hypertensive episodes. The hypertensive episodes were defined as: 1.
a period of at least 10 mmHg increase in the systolic blood
pressure (SBP) between the start and the end of a dialysis session,
or, 2. hypertension occurring after significant ultrafiltration was
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immediately after the dialysis procedure [2,6]. During hemodial-
ysis, blood pressure was also measured at 20 minute intervals using
a digital oscillometric sphygmomanometer. During hypertensive
episodes, blood pressure was double-checked by two different
nurses or technicians every 5 minutes. The intradialytic episodes
(n=62) of increased blood pressure were further divided according
to IBI changes into: a) episodes with decreased IBI, when the increase
of at SBP was associated with a parallel increase in heart rate
(n=45) and, b) episodes with increased IBI, when the SBP increase
was accompanied a decrease in heart rate (n=17). Representative
tracings of hypertensive episode associated with increased or decreased
rate are depicted in Figure 1, left and mid panels. An episode with
intradialytic hypotension and increased heart rate is depicted for
comparison in the right panel.
Complex demodulation
Complex demodulation is a nonlinear time domain method of
time series analysis. It is suited to the investigation of nonstationary
oscillations and reveals instantaneous dynamic changes that are
not revealed by the power spectrum methods. The analysis used in
the present study was based on technique of Hayano et al [35]. In
this analysis, signal X (t) is assumed to contain a frequency
component which changes slowly around a specified center
frequency, while Y(t) is the complex signal after shifting the
frequency band around the frequency of interest to zero (see
Methods S1).
Complex demodulation of SBP and IBI signals was performed
at two frequency bands. The central frequencies (f0) were 0.09 Hz
for the low frequency (LF) and 0.30 Hz for the high frequency
(HF) band. The result was then filtered by a low-pass 16th degree
Butterworth filter with cut-off frequencies of 0.05 Hz and 0.16 Hz
for the low and high frequencies range respectively. The signals
were then smoothed by a 201 point least-square moving
polynomial. Complex demodulation baroreflex (BRS) time series
was computed as the ratio of the IBI and SBP time series
instantaneous values in the two frequency ranges.
The amplitudes of SBP, IBI and BRS changes in the low
(around center frequency of 0.09 Hz) and high (around center
frequency of 0.30 Hz) frequency ranges were followed during the
Table 1. Demographic and clinical data of all patients and of patients without and with hypertensive episodes.
All Patients (n=108)
Without
hypertension
(n=51)
With hypertension
(n=57) p
a
Age (years)
b 58 (15) 56 (16) 60 (15) 0.216
Males/females 69/39 32/19 37/20 0.815
Dialysis vintage (years)
b 1.90 (3.02) 2.21 (3.51) 1.61 (2.49) 0.304
History of hypertension [n (%)] 98 (90.7) 45 (88.2) 53 (93.0) 0.396
Diabetes mellitus [n (%)] 38 (35.2) 18 (35.3) 20 (35.1) 0.982
History of ischemic heart disease [n (%)] 62 (57.4) 25 (49.0) 37 (64.9) 0.095
LV systolic dysfunction [n (%)]
c 28 (27.2)* 12 (23.5) 16 (30.8) 0.409
Diastolic dysfunction [n (%)] 37 (40.7)** 15 (34.1) 22 (46.8) 0.217
History of hyperlipidemia [n (%)] 79 (73.1) 37 (72.5) 42 (73.7) 0.894
History of frequent hypotensive episodes [n (%)] 53 (49.1) 23 (45.1) 30 (52.6) 0.434
Antihypertensive medication [n (%)] 80 (74.1) 36 (70.6) 44 (77.2) 0.578
Nitrates [n (%)] 20 (18.5) 5 (9.8) 15 (26.3) 0.027
Calcium blocking agents [n (%)] 40 (37.0) 15 (29.4) 25 (43.9) 0.121
Vasodilators
d [n (%)] 20 (18.5) 3 (5.9) 17 (29.8) 0.001
ACE inhibitors [n (%)] 24 (22.2) 10 (19.6) 14 (24.6) 0.536
Angiotensin receptor blockers [n (%)] 10 (9.3) 4 (7.8) 6 (10.5) 0.631
Beta-blockers [n (%)] 55 (50.9) 25 (49.0) 30 (52.6) 0.708
Plasma Creatinine (mmol/l)
b,e 728 (200) 757 (208) 702 (190) 0.154
Plasma calcium (mmol/l)
b, e 2.22 (0.19) 2.24 (0.20) 2.21 (0.19) 0.434
Plasma phosphate (mmol/l)
b, e 1.55 (0.36) 1.56 (0.37) 1.54 (0.36) 0.848
Hb (g/dl)
b, e 11.1 (1.2) 11.1 (1.1) 11.2 (1.3) 0.751
Plasma albumin (g/l)
b, e 38.0 (4.2) 38.7 (3.8) 37.4 (4.4) 0.112
PTH (pmol/l)
b, e 49 (41) 51 (39) 48 (43) 0.684
CRP (mg/dl)
b, e 3.36 (4.31) 2.85 (3.67) 3.82 ( 4.80) 0.254
aWith vs. without hypertension.
bMean (SD).
cLeft ventricular ejection fraction (LVEF),40%.
dDoxasozine or hydralazine.
ePredialysis values.
*Assessed in 103 patients, 52 with hypertensive episodes.
**Assessed in 91 patients, 47 with hypertensive episodes.
ACE, angiotensin-converting enzyme; CRP, C-reactive protein; Hb, hemoglobin; LV, left ventricle; PTH, parathyroid hormone.
doi:10.1371/journal.pone.0036943.t001
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All Patients (n=108)
Without hypertension
(n=51)
With hypertension
(n=57) p
a
Predialysis SBP (mmHg)
* 134 (25) 135 (27) 133 (23) 0.694
Intradialytic weight loss (% of body weight)
b 27.5 (15.3)** 28.1 (15.7) 26.9 (15.1) 0.714
Ultrafiltration rate (ml/min)
b 9.29 (4.62)** 9.56 (4.67) 9.10 ( 4.57) 0.630
Dialysate Na concentration
[n (%)]
,140 mmol/l 2 (1.9) 1 (2.0) 1 (1.8) 0.663
140 mmol/l 98 (90.7) 45 (88.2) 53 (93.0)
.140 mmol/l 8 (7.4) 5 (9.8) 3 (5.2)
Predialysis plasma Na (mmol/l)
b 139 (3) 139 (3) 139 (3) 0.340
Postdialysis plasma Na (mmol/l)
b 140 (3)
c 141 (4)
c 140 (3)
d 0.245
Gradient between dialysate and plasma Na (mmol/l)
b 1.20 (3.52) 1.00 (3.70) 1.39 (3.38) 0.572
Increase in plasma Na after dialysis (mmol/l)
b 1.37 (2.98) 1.45 (3.02) 1.30 (2.97) 0.792
Predialysis plasma K (mmol/l)
b 4.97 (0.65) 5.10 (0.76) 4.85 (0.65) 0.065
Postdialysis plasma K (mmol/l)
b 3.54 (0.43)
c 3.63 (0.37)
c 3.45 (0.47)
c 0.030
Increase in plasma K after dialysis (mmol/l)
b 1.43 (0.62) 1.47 (0.62) 1.40 (0.62) 0.537
Predialysis plasma osmolality (mosm/KgH2O)
b 318 (12) 319(10) 316 (12) 0.187
Postdialysis plasma osmolality (mosm/KgH2O)
b 305 (8)
c 307 (8)
c 303 (8)
c 0.054
*Data given as median and interquartile range.
**Data available in 97 patients (53 with hypertensive episodes).
aWith vs. without hypertension.
bMean (SD).
p vs. predialysis values:
c,0.001;
d0.002.
doi:10.1371/journal.pone.0036943.t002
Figure 1. Representative tracings of continuous recordings of SBP and IBI oscillations and variability during intradialytic
hypertension episodes with decreased (A) or increased heart rate (B). Tracings of a patient with marked intradialytic hypotension are depicted
for comparison (C). The episodes associated with sudden changes in blood pressure are shown by the bolder parts of the tracings. LF, low frequency;
HF, high frequency; IBI, interbeat interval.
doi:10.1371/journal.pone.0036943.g001
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SBP, LF and HF IBI, LF IBI/HF IBI ratio (representative of
sympatho-vagal balance) and BRS indices were calculated the
following manually detected periods: 1) the first 20 minutes
(beginning), 2) the last 20 minutes (end) of dialysis, 3) 20 minutes
before, and, 4) during hypertensive episodes.
Statistics
Demographic and clinical categorical variables were compared
by chi-square test. Age and laboratory data (mean and standard
deviation) were compared using Student’s t test. Blood pressure,
inter-beat interval and baroreceptor variables are given as medians
and inter-quartile ranges.
Wilcoxon signed-ranks test was used to compare paired
differences at the beginning and the end of dialysis and to assess
differences between the periods before and during hypertensive
episodes. Mann-Whitney U-test was used to compare between
sessions without and with hypertension, and between hypertensive
episodes with increased and decreased heart rate.
Correlations of intradialytic changes in SBP with CDM indices
and between different CDM variables were performed by Pearson
correlation and linear regression analysis.
Logistic regression analysis
Logistic regression analysis (stepwise forward conditional
procedure) was performed to select determinants of intradialytic
hypertension. Age, gender, hemodialysis vintage (years), the
presence of diabetes mellitus, history of hypertension, hyperlipi-
demia , ischemic heart disease and of intradialytic hypotensive
episodes, administration of antihypertensive drugs, hypertensive
medication, biochemical data and predialysis SBP, IBI and CDM
measurements (LF IBI, HF IBI, LF SBP, HF SBP, LF BRS and
HF BRS) were all included in the analysis.
Definitions of clinical variables
Ischemic heart disease was defined by: documentation of prior
myocardial infarction or of coronary interventions, the presence of
significantly abnormal Q waves on a 12-lead electrocardiogram,
symptomatic angina pectoris or a thallium perfusion scan
suggestive of myocardial ischemia. Left ventricular systolic
dysfunction was defined as decreased left ventricular ejection
fraction (LVEF) to less than 40% on echocardiography. Doppler
interrogation of the mitral valve, pulmonary vein and mitral
annulus was used to assess diastolic function. Severe diastolic
dysfunction was defined as :a) pseudo-normalization of E (early
filling wave) to A (late filling wave) ratio, suggesting an elevated left
ventricular diastolic pressure, or, b) a restrictive pattern, suggesting
reduced compliance, i.e. grade 2–4 diastolic dysfunction by
echocardiographic criteria [39]. Patients with high triglyceride
or/and high LDL cholesterol levels were considered to be
hyperlipidemic.
Results
Clinical and laboratory data
One hundred and eight patients were examined during 113
hemodialysis sessions. Hypertensive episodes (n=62) were detect-
ed in 57 patients. The timing of the occurrence of the hypertensive
episode was different for each patient. Ten episodes occurred in
the 1
st, 22 in the 2
nd and 24 in the 3
rd hour, and 6 towards the end
of hemodialysis session. The duration (mean 6 SD) of the
hypertensive episodes was 27616 min (range 5–80 min). While
many patients with intradialytic increases in blood pressure
episodes complained of dizziness, palpitations or weakness, none
developed syncope or loss of consciousness.
Patient clinical and biochemical data are listed in Table 1. Pre-
and post dialysis SBP and other data related to the hemodialysis
procedure are listed in Table 2. Age, sex distribution and dialysis
vintage were similar in patients without and with intradialytic
hypertensive episodes (Table 1). Diabetic nephropathy was the
primary renal disease in 15 (29.4%) and in 18 (31.6%) patients
without and with hypertensive episodes, respectively. Other causes
of end stage renal failure in patients without and with intradialytic
hypertension were glomerulonephritis (10 and 11), interstitial
nephritis (5 and 5), familial nephropathy in 6 (6 and 3),
nephrosclerosis and ischemic nephropathy (3 and 8), autosomal
dominant polycystic kidney disease (1 and 3) and miscellaneous (11
and 9). A residual renal function was present in 44 patients, 17
without (mean creatinine clearance 5.87(4.12) ml/min) and 27
with intradialytic hypertension (mean creatinine clearance
5.29(3.65) ml/min, pNS). A history of essential or secondary
hypertension was in the medical background of 45 (88.2%) and 53
(93%) patients without and with intradialytic hypertensive
episodes, respectively (p NS). While the prevalence of diabetes
mellitus, hyperlipidemia and the dialysis vintage was similar in
both groups, that of ischemic heart disease was slightly increased in
patients with hypertensive episodes (p=0.095) . Fifty three (49.1%)
patients, 23 patients with and 30 without hypertensive episodes (p
NS) had a history of frequent hypotensive episodes during dialysis.
The prevalence of patients receiving antihypertensive drugs was
comparable in both groups, but the use of vasodilators and nitrates
was more frequent in patients with intradialytic hypertensive
episodes. There were no significant differences between groups
with regard to cardiac function, biochemical data, dialysis
prescription, intradialytic weight loss or ultrafiltration rate. While
the decrease in plasma K
+ was similar in both groups, post dialysis
K
+ level was lower in patients with hypertensive episodes (Table 2).
Effect of hemodialysis treatment on autonomic activity
and on baroreceptor sensitivity in patients without and
with intradialytic hypertensive episodes
Table 3 lists blood pressure, interbeat intervals and their
variabilities, baroreflex sensitivity indices and LF IBI/HF IBI ratio
during all screened hemodialysis sessions (n=113), and sessions
without (n=51) and with (n=62) hypertensive episodes. There
was a significant decrease in SBP at the end of hemodialysis
sessions without hypertensive episodes, while in those with
hypertensive episodes, there were marked increases in SBP, DBP
and MBP. A minimal decrease in LF SBP was noted, especially in
session without hypertension, while HF SBP significantly increased
at the end of dialysis in both groups. In both types of sessions, IBI
was not significantly changed at the end of the dialysis. At the
beginning of dialysis, LF BRS and HF BRS were higher in sessions
associated with hypertensive episodes. Significant increases in LF
IBI, HF IBI and LF BRS, and a decrease in LF IBI/HF IBI at the
end of the treatment occurred only in the dialysis sessions without
hypertension.
Blood pressure and interbeat interval variability,
baroreflex sensitivity and sympatho-vagal balance during
intradialytic hypertensive episodes
Forty-five (72.5%) intradialytic hypertensive episodes (mean
duration 24614 min) in 41 patients were associated with an
increase in heart rate; the heart rate decreased during 17 (27.5%)
episodes in 16 patients (lasting 34619 min, p NS).The timing of
occurrence of hypertension during dialysis was similar in the two
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examinations; one patient was examined 3 times, and the
remaining 3 patients were examined twice. Intradialytic hyper-
tensive episodes with increased heart rate were detected during
repeated examinations in 3 patients; in one remaining patient
intradialytic increase in blood pressure with decreased heart rate
was detected during two separate sessions.
During hypertensive episodes, the magnitude of the increase in
blood pressure was similar in both subgroups. Maximal SBP, DBP
and MBP [median (interquartile range)] were 158 (30), 80 (24) and
104 (19) mm Hg in patients with increased heart rate (p,0.001 vs.
before) and 159 (25), 73 (17) and 102 (19) mm Hg in patients with
decreased heart rate (p,0.001 vs. before). SBP, IBI and their
variability before and during hypertensive episodes are depicted in
Figure 2, while baroreceptor sensitivity indices and LF IBI/HF IBI
during intradialytic hypertension are shown in Figure 3. At the
initiation of hypertensive episodes (before), blood pressure and IBI
were similar in all patients. LF SBP, HF SBP and LF IBI markedly
increased during the hypertensive episodes in patients with increased
heart rate (decreased IBI) , but did not significantly change in
those in whom heart rate decreased (increased IBI, Figure 2). In
increased heart rate episodes, the blood pressure elevation was
associated with significantly diminished baroreflex indices (LF
BRS and HF BRS) and enhanced LF/HF ratio (Figure 3). In
decreased heart rate episodes, a tendency to increase in BRS indices
was observed during hypertension; these changes, however, were
not statistically significant.
Significant correlations between changes in heart rate variability
with changes in blood pressure variability in both LF (r=0.526)
and HF (r=0.405) bands (p,0.001) were found during hyperten-
sive episodes, but only in those with increased heart rate (Figure 4).
We found no correlations between the blood pressure increases
during hypertensive episodes with changes in heart rate variability
or blood pressure variability, with changes in baroreflex indices or
LF IBI/HF IBI ratio. Likewise, there were no correlations between
blood pressure increases and weight loss, ultrafiltration rate, the
dialysate to predialysis plasma Na concentration gradient or the
decrease in plasma potassium and in plasma osmolality during
dialysis.
Comparisons of patients experiencing intradialytic hypertension
with increased or decreased heart rate showed that age, medical
history and comorbidities, the number of years in dialysis, dialysis
prescription and the biochemical profile were similar for the two
subgroups (not shown). A higher proportion of women, 9 of 16,
was noted, however, in the subgroup of patients with decreased
heart rate as compared with 11 of 41 in patients with increased
heart rate during hypertensive episodes (p=0.036). In addition, in
the former subgroup, 8 (50%) patients were treated with an
angiotensin converting enzyme inhibitor as compared with 6
(14.6%) patients in the latter (p=0.005). Pre-and post-dialysis
SBP, DBP, IBI and CDM measurements were similar in patients
with increased or decreased heart rate during intradialytic
hypertension episodes.
Predictors of intradialytic hypertension
Logistic regression analysis (stepwise forward conditional
procedure) was performed to define independent predictors of
intradialytic hypertension. Three different models were construct-
ed including clinical, dialysis and laboratory data and CDM
measurements (see Methods). The most significant predictors are
listed in Table 4. Predialysis baroreflex sensitivity in the low
frequency range (LF BRS) was found to be the most important
predictor of intradialytic hypertension (1
st and 2
nd models, Odds
Ratio 1.455 and 1.650, p=0.004 and 0.001, respectively). Because
of the strong correlation of baroreflex sensitivity with heart rate
variability and the inverse correlation with blood pressure
variability [28], these indices were analyzed in a different model
(3
rd model). In this model, a higher predialysis LF IBI (Odds ratio
1.228, p=0.006) and a lower LF SBP (Odds ratio 0.223,
Table 3. Blood pressure variability, baroreflex sensitivity indices, interbeat intervals and low frequency/high frequency interbeat
interval ratio at the beginning and at the end of hemodialysis*.
All sessions (n=113)**
Sessions without hypertension
(n=51)** Sessions with hypertension (n=62)**
Beginning End p Beginning End p Beginning End p
SBP (mmHg) 135 (31) 134 (36) 0.160 139 (42) 125 (34) 0.023 132 (30) 143 (36)
c 0.001
DBP (mmHg) 67 (18) 73 (17) 0.001 69 (19) 71 (18) 0.056 67 (17) 76 (21)
d 0.001
MBP(mmHg) 90 (20) 94 (22) 0.001 92 (25) 90 (16) 0.888 90 (17) 100 (17)
c 0.001
IBI (msec) 827 (177) 862(216) 0.103 802 (196) 813(274) 0.606 850 (162) 878 (175) 0.089
LF SBP (mmHg) 1.92 (2.02) 1.90 (0.87) 0.726 1.98 (0.93) 1.95 (1.00) 0.051 1.92 (0.64) 1.88 (0.86) 0.188
HF SBP (mmHg) 1.40 (0.72) 1.69 (0.70) 0.001 1.54 (0.58) 1.89 (1.01) 0.003 1.21 (0.72)
b 1.64 (0.52) 0.003
LF IBI (msec) 5.79 (4.74) 6.95 (6.38) 0.022 5.39 (4.49) 6.01 (6.80) 0.046 6.11 (4.92) 7.16 (5.49) 0.165
HF IBI (msec) 5.52 (3.28) 5.85 (4.07) 0.001 4.99 (2.45) 5.82 (5.32) 0.001 5.81 (3.39) 5.87 (2.77) 0.369
LF BRS (msec/mmHg) 3.48 (2.51) 3.60 (2.85) 0.003 3.03 (1.95) 3.21 (3.20) 0.001 3.62 (2.79)
a 3.67 (2.67) 0.468
HF BRS (msec/mmHg) 3.87 (2.91) 3.69 (3.41) 0.783 3.29 (2.62) 3.42 (4.52) 0.376 4.39 (3.13)
b 3.89 (2.54) 0.147
LF IBI/HF IBI 1.11 (0.59) 1.06 (0.50) 0.034 1.15 (0.64) 1.04 (0.58) 0.003 1.07 (0.57) 1.07 (0.60) 0.809
*Data given as median and interquartile range;
**Number of patients: all sessions-108; without hypertension-51; with hypertension-57. Beginning-the initial 20 minutes of the dialysis session; End-the last 20 minutes
of the dialysis session. Comparison of sessions without and with hypotension-Beginning:
ap=0.004;
bp=0.008; End:
cp=0.001;
dp=0.035.
doi:10.1371/journal.pone.0036943.t003
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episodes.
Other significant predictors were lower serum albumin level (2
nd
and 3
rd models, p=0.020 and 0.037) and age (2
nd model,
p=0.037).
Discussion
This study is the first, to our knowledge, to report on dynamic
changes of SBP, IBI and baroreflex function during intradialytic
hypertensive episodes. The principal new finding of this study is
that a large proportion of hypertensive episodes are associated
with increased heart rate, with marked increases in blood pressure
variability (LF SBP and HF SBP), interbeat interval variability (LF
IBI), decreased baroreceptor sensitivity (LF BRS and HF BRS)
and enhanced sympatho-vagal balance (Figure 2 and 3).The above
episodes, characterized by shortening of IBI intervals synchronous
with SBP increase, are similar to those occurring during central
autonomic activations [40]. These non- baroreceptor- related
events are believed to be mediated by enhanced sympathetic
outflow with feed-forward effects on blood pressure [41]. In
contrast, during baroreceptor activation, increases or decreases in
blood pressure are associated with feed-back mediated decreases
or increases in heart rate (increased or decreased interbeat
interval), respectively. In hemodialysis patients, baroreflex mech-
anisms were shown to be adequately activated during hypotensive
episodes [36]. Our present findings suggest that sympathetic
activation and feed–forward enhancement of blood pressure play
an important role in the pathogenesis of intradialytic hypertension
episodes.
Sympathetic activation during intradialytic hypertensive
episodes
Sympathetic overactivity associated with chronic hypertension
was detected by MSNA in patients with early or advanced chronic
kidney disease and on maintenance hemodialysis [17,18,25,29,42].
In one single study, performed during dialysis, the sympathetic
firing was shown to increase during the hemodialysis procedure,
ultrafiltration and decrease in blood pressure [18].
Figure 2. SBP and interbeat interval and their variability indices before and during intradialytic hypertensive episodes associated
with increased (n=45) or decreased (n=17) heart rate. Data are presented as box plots. The box stretches from the 25
th to the 75
th percentile;
the median is shown as a small black square in the box. The range (the upper and the lower extreme values) is indicated by whiskers. HF, high
frequency; LF, low frequency, IBI, interbeat interval.
doi:10.1371/journal.pone.0036943.g002
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SBP was increased, while LF IBI and the baroreceptor sensitivity
indices were markedly decreased as compared to normal
individuals [43].These findings, similar to those reported in
essential hypertension and congestive heart failure, were inter-
preted as evidence of background chronic sympathetic overactivity
associated with end-stage kidney disease.
In the present study, the alterations noted during 45 (72.5%) of
62 intradialytic hypertensive episodes (Figures 2 and 3) are
suggestive of acute bursts of sympathetic activity with feed forward
enhancement of blood pressure. In the remaining 17 hypertensive
episodes, similar increases in blood pressure were associated with
decreased heart rate; no significant changes in interbeat interval
variability, blood pressure variability or baroreflex indices were
noted in these patients. One possible explanation for these findings
may involve simultaneous co-activation of the parasympathetic
system resulting in an elevated blood pressure without an increase
in heart rate, as described in subjects under psychological stress
[44]. The intradialytic elevation in blood pressure with no increase
in heart rate might also be caused by mechanisms independent of
autonomic nervous-system. Endothelial dysfunction was recently
documented in patients with intradialytic hypertension [14,45]; in
one study intradialytic hypertension was independently associated
with both endothelial dysfunction and increased arterial stiffness
[45]. Accordingly, a primary functional defect within the arterial
wall may lead under special circumstances to an exaggerated
pressure response due to increased endothelin and decreased nitric
oxide (NO) availability and increased vascular resistance [14,15].
The mechanisms of acute intradialytic activation of the
sympathetic nervous system are not well defined. Activation of
RAS was suggested as a potential mechanism of both sympathetic
stimulation and intradialytic hypertension. A recent study,
however, did not show increases in plasma renin and aldosterone
levels during hemodialysis in patients with intradialytic increases in
blood pressure [15]. In our study, end-of dialysis plasma potassium
level was lower in patients with hypertensive episodes. The lower
plasma potassium in these patients could indeed have resulted
from intradialytic activation of the renin-angiotensin system,
leading to increased circulating angiotensin and aldosterone levels,
with further activation of central nervous system mineralocorticoid
and angiotensin type I receptors and enhanced sympathetic
outflow [25,46]. In hemodialysis patients, an acute decrease in
serum potassium was shown to be associated with increased blood
pressure, presumably mediated by arteriolar constriction via
sympathetic stimulation [8].
Another proposed mechanism extensively investigated in
chronic kidney disease links between renal ischemia and hypoxia,
activation of mechano- and chemo-receptors, secretion of aden-
osine and sympathetic activation [42]. The relevance of this
mechanism, however, for hemodialysis-associated hypertension
remains to be determined.
Tonic arterial chemoreceptor activation was also shown to be
involved in sympathetic activation in patients with advanced renal
failure [47]. Hypoxemic events during hemodialysis, initiated by
intrapulmonary (ventilation-perfusion mismatching) and/or extra-
pulmonary (ventilatory control) mechanisms [48] may elicit
sympathetic activation [47]. Peripheral chemoreflex sensitivity is
particularly enhanced in patients with obstructive sleep apnea, a
common condition in chronic hemodialysis and frequently
associated with hypertension. [49]. Studies in experimental
animals have shown that prolonged blood flow reduction to
carotid body enhances chemoreflex function and causes sympa-
thetic activation [50]. Alterations of cerebral blood flow may occur
in association with hemodynamic changes during hemodialysis
[51].Taken together, these findings strongly support the hypothesis
that sympathetic overactivity may be triggered by chemoreceptor
dysregulation associated with fluid and electrolyte shifts during
hemodialysis.
Figure 3. BRS indices and LF IBI/HF IBI ratio before and during
intradialytic hypertensive episodes associated with increased
(n=45) or decreased (n=17) heart rate. Data are presented as box
plots. The box stretches from the 25
th to the 75
th percentile; the median
is shown as a small black square in the box. The range (the upper and
the lower extreme values) is indicated by whiskers. BRS, baroreceptor
sensitivity; HF, high frequency; LF, low frequency, IBI, interbeat interval.
doi:10.1371/journal.pone.0036943.g003
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lytic sympathetic activation may be related to a reduced vascular
and hypothalamic availability of nitric oxide (NO) associated with
alterations in sympathetic outflow and in vascular endothelial
function [13,15,52]. Deficiency of the soluble monoamine oxidase
renalase in end stage renal failure was also shown to be associated
with increased sympathetic tone and with resistant hypertension
[53]. The activation of the above mechanisms during intradialytic
hypertensive episodes has yet to be explored.
Figure 4. Correlations of changes in interbeat intervals with changes in SBP during intradialytic hypertensive episodes associated
with increased (n=45) or decreased (n=17) heart rate. HF, high frequency; LF, low frequency, IBI, interbeat interval.
doi:10.1371/journal.pone.0036943.g004
Table 4. Predictors of intradialytic hypertension based on logistic regression analysis.
Variables Predictors Odds ratio 95% CI b coefficient p
1
st Model (Clinical data, LF BRS and HF BRS) LF BRS 1.455 1.130–1.875 0.375 0.004
2
nd Model (Clinical and laboratory data,
LF BRS and HF BRS)
Age 1.032 1.002–1.063 0.031 0.037
Plasma albumin 0.875 0.781–0.979 20.134 0.020
LF BRS 1.650 1.222–2.228 0.501 0.001
3
rd Model (Clinical and laboratory data,
LF IBI, HF IBI, LF SBP, HF SBP)
Albumin 0.892 0.801–0.993 20.114 0.037
LF IBI 1.228 1. 061–1.422 0.206 0.006
LF SBP 0.223 0.089–0.561 21.499 0.001
CI: confidence interval.
Variables in logistic regression models:
Clinical data: age, gender, dialysis vintage, history of intradialytic hypotension, history of hypertension, diabetes, ischemic heart disease, hyperlipidemia, anti-
hypertensive medication, pre-dialysis SBP and IBI.
Laboratory data: pre-dialysis creatinine, calcium, phosphate, potassium, albumin, hemoglobin and PTH concentrations and CRP levels.
CDM measurements: pre-dialysis LF IBI, HF IBI, LF SBP, HF SBP, LF BRS and HF BRS.
doi:10.1371/journal.pone.0036943.t004
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excess were proposed and are still believed by many investigators
to be the main causes of intradialytic and interdialytic hyperten-
sion [2,7,54,55]. In experimental animals, excess salt may lead to
hypertonic Na accumulation in skin, to endothelial activation and
hypertension [56,57]. A central effect of excessive salt intake may
occur via enhancement of the excitability of sympatho-regulatory
circuits in the rostral ventro-lateral medulla and it was hypoth-
esized that even small changes in plasma sodium may affect the
responsiveness of these neurons [57]. Salt balance may also affect
sympathetic activity via modulation of renalase expression [53].
Dialysis salt loading may occur with increased dialysate Na
concentration and/or with increased dialysate to predialysis
plasma Na gradient [55]. Indeed, a mild but significant increase
in plasma sodium concentration was noted after dialysis in all our
patients (Table 2). Pre-and post dialysis plasma Na and the
dialysate to predialysis Na concentration gradient, however, were
similar in patients without and with hypertension (Table 2), and in
hypertensive patients with increased as compared with those with
decreased heart rate (see Results). Furthermore, these indices did
not predict the occurrence of hypertensive episodes in the logistic
regression models (Table 4). Thus, while a positive salt balance
might be present in many of our patients, it could not explain the
sudden increase in blood pressure or spontaneous bursts of
sympathetic activity occurring during dialysis.
Predictors of intradialytic hypertensive episodes
On logistic regression analysis, a higher predialysis BRS in the
low frequency band (LF BRS) was found to be the main predictor
of intradialytic hypertension (Table 4). Indeed, both LF BRS and
HF BRS were higher at the beginning of dialysis sessions
associated with intradialytic hypertension as compared with
sessions without hypertensive episodes (Table 3). LF IBI was also
higher, albeit not significantly at the beginning of hypertensive
sessions. The increased initial BRS and LF IBI may suggest the
presence of a more robust autonomic nervous system in patients
with intradialytic hypertension and may be interpreted as resulting
from the synergistic effect of enhanced sympathetic tone coupled
with reflex vagal activation [58]. A recent paper underscores the
dependency of the sympathetic baroreflex with the level of
sympathetic activity at rest especially in young and old men and in
postmenopausal women [59]. Extrapolation of these findings to
our study, however, has to be done cautiously, in view of the
different methodology and different study population. Genetic
traits, including polymorphism of RAS genes [60] or of beta-
adrenergic receptors [61] that affect autonomic activity and BRS
were also not checked in the present study.
Comparisons of patients with and without hypertensive episodes
(Table 1) shows a slightly higher ratio of ischemic heart disease and
an increased proportion of patients treated with nitrates, calcium
channel blockers and vasodilator drugs in the hypertensive group.
These conditions, however, were reported to be most commonly
associated with decreased or no significant changes in BRS [62–
65]. The proportion of patients treated with beta blocker agents
and with angiotensin receptors antagonists (ARB’s) that may both
increase BRS [66,67] was similar in patients with and in those
without hypertension. When compared with patients with
increased heart rate, a higher proportion of those with decreased
heart rate were treated with ACE inhibitors. These agents were
shown to enhance heart rate variability and increased baroreflex
sensitivity [68]. Even though antihypertensive medication was
stopped in all patients at least 12 hr before the study, a partial
effect of drugs on CDM measurements can not be excluded.
Other predictors of intradialytic hypertension in the present
study were lower plasma albumin and age. These factors may be
suggestive of the link between autonomic imbalance and chronic
inflammation in elderly individuals and in patients with end stage
renal disease on maintenance hemodialysis [69,70]. The correla-
tion of these markers with intradialytic hypertension has yet to be
understood.
Intradialytic hypertension may contribute to interdialytic
hypertension
The second important finding of this study is the markedly
increased end-of-dialysis blood pressure in patients with intradia-
lytic hypertensive episode (Table 3) as compared with the
remaining patients, in which end-of dialysis blood pressure
decreased. This finding confirms previous observations from other
studies [54,71]; in one such study, intradialytic hypertension was
associated with increased time-integrated blood pressure burden as
measured by 44-hour ambulatory monitoring [71]. In our study,
end-of dialysis blood pressure was similar in patients with
hypertensive episodes with increased or decreased heart rate (not
shown in tables). We did not find differences in ultrafiltration rates,
intradialytic weight loss, pre-and post-dialysis plasma sodium
concentration or dialysate sodium concentration between patients
with and those without hypertensive episodes. Since blood volume
monitoring techniques were not available, our patients’ dry
weight, however, was assessed by clinical criteria only. Thus, a
residual volume and/or sodium excess in certain patients could
not be ruled out, especially in the presence of a positive dialysate to
plasma Na concentration gradient (Table 2). Chronic volume
excess is thought to be the main cause of interdialytic hyperten-
sion. Within this regard our study corroborates the assumption
that intradialytic hypertension may play a role in the generation of
interdialytic hypertension [54].
Limitations
One main shortcoming of our study is the use of noninvasive
methodology of assessment of autonomic nervous function, since
more direct techniques as MNSA or pharmacological challenge
were not applicable to our patient population. The study patient
population included many elderly individuals with multiple
comorbidities. These patients however, are most characteristic of
the present day general hemodialysis population. Likewise,
because of the methodology limitations, patients with arrhythmia
or pacemakers were excluded from the study. Furthermore, blood
volume and hemodynamic parameters were not assessed in
parallel with the CMD determinations.
Perspectives
Our findings support the hypothesis that increased sympathetic
activity mediates intradialytic hypertension. Intradialytic hyper-
tensive episodes with elevated post-dialysis blood pressure may
contribute to interdialytic hypertension. This association deserves
further studies using hemodynamic monitoring, different dialysis
protocols and pharmacological approaches. The prognostic
impact of intradialytic sympathetic activation and hypertension
on overall survival and cardiovascular morbidity of these patients
remain to be further clarified.
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